BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gong J, Hendifar A, Gangi A, Zaghiyan K, Atkins K, Nasseri Y, Murrell Z, Figueiredo JC, Salvy S, Haile R, Hitchins M. Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer. Cancers (Basel) 2021;13:4547. [PMID: 34572774 DOI: 10.3390/cancers13184547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Choi WJ, Ivanics T, Gravely A, Gallinger S, Sapisochin G, O'Kane GM. Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring. Ann Surg Oncol 2023. [PMID: 36808320 DOI: 10.1245/s10434-023-13126-x] [Reference Citation Analysis]
2 Hofste LSM, Geerlings MJ, von Rhein D, Rütten H, Westenberg AH, Weiss MM, Gilissen C, Hofste T, van der Post RS, Klarenbeek BR, de Wilt JHW, Ligtenberg MJL; Libic2 collaborators group. Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer. Eur J Surg Oncol 2023:S0748-7983(23)00093-8. [PMID: 36740555 DOI: 10.1016/j.ejso.2023.01.026] [Reference Citation Analysis]
3 Chan HT, Nagayama S, Otaki M, Chin YM, Fukunaga Y, Ueno M, Nakamura Y, Low SK. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Front Oncol 2022;12:1055968. [PMID: 36776372 DOI: 10.3389/fonc.2022.1055968] [Reference Citation Analysis]
4 Dayyani F, Smith BR, Nguyen NT, Daly S, Hinojosa MW, Seyedin SN, Kuo J, Samarasena JB, Lee JG, Taylor TH, Cho MT, Senthil M. A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC). Future Oncol 2022. [PMID: 35603628 DOI: 10.2217/fon-2022-0285] [Reference Citation Analysis]